Table 2.
Variable | Diabetes (n = 120) | Hypertension (n = 65) | Hypertension and diabetes (n = 23) | Total (n = 208) | P-value |
---|---|---|---|---|---|
uPCR | |||||
<3 mg/mmol | 102 (85.0) | 52 (80) | 7 (30.4) | 161 (77.4) | p < 0.001 |
3–30 mg/mmol | 18 (15.0) | 10 (15.4) | 15 (65.2) | 43 (20.7) | |
>30 mg/mmol | 0 (0.0) | 3 (4.6) | 1 (4.3) | 4 (1.9) | |
eGFR, mL/min/1.73 m2 n (%) | |||||
≥90 | 39 (33) | 16 (25) | 5 (22) | 60 (29) | p < 0.001 |
60–89 | 54 (45) | 39 (60) | 5 (22) | 98 (47) | |
45–59 | 15 (13) | 1 (1.5) | 3 (13) | 19 (9.1) | |
30–44 | 9 (7.5) | 5 (7.7) | 4 (17) | 18 (8.7) | |
15–29 | 3 (2.5) | 4 (6.2) | 6 (26) | 13 (6.2) | |
<15 | 0 0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
CKD n (%) | |||||
Stage 1: eGFR ≥90 + Alb | 1 (0.8) | 1 (1.5) | 1 (4.3) | 3 (1.4) | 0.16 |
Stage 2: eGFR 60–89 + Alb | 4 (3.3) | 3 (4.6) | 3 (13.0) | 10 (4.8) | |
Stage 3a: eGFR 45–59 | 15 (12) | 1 (1.5) | 3 (13.0) | 19 (9.1) | |
Stage 3b: eGFR 30–44 | 9 (7.5) | 5 (7.7) | 4 (17) | 18 (8.7) | |
Stage 4: eGFR15–29 | 3 (2.5) | 4 (6.2) | 6 (26) | 13 (6.3) | |
Stage 5: eGFR < 15 | 0 | 0 | 0 | 0 | |
Total CKD, n (%) | |||||
(Stages 1–5) | 32 (27) | 14 (22) | 17 (74) | 63 (30) |
Note to authors: the reference here should be a citation and should be to the earlier version of the guidelines that used the staging terminology
We include stages as described in earlier KDIGO guidelines (KDIGO 2013) for the purposes of comparison with other studies
uPCR rine protein-creatinine ratio, eGFR estimated GFR, CKD chronic kidney disease